Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker SANA
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | Abigail P. Johnson | 37.29M | 12.5% | SCHEDULE 13G/A ↗ |
| Nov 5, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | FMR LLC | 37.29M | 12.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | Kristina Burow | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | Steven Gillis | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | Robert Nelsen | 46.17M | 15.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | Clinton Bybee | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | Keith Crandell | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Partners X, LLC | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Partners IX, LLC | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Partners X, L.P. | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Partners X Overage, L.P. | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Partners IX Overage, L.P. | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Partners IX, L.P. | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Fund X Overage, L.P. | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Fund X, L.P. | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Fund IX Overage, L.P. | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Fund IX, L.P. | 45.86M | 15.3% | SCHEDULE 13G/A ↗ |
| May 21, 2026 | SCHEDULE 13G | SANA Sana Biotechnology, Inc. | RA Capital Healthcare Fund, L.P. | 18.75M | 6.3% | SCHEDULE 13G ↗ |
| May 21, 2026 | SCHEDULE 13G | SANA Sana Biotechnology, Inc. | Rajeev Shah | 18.75M | 6.3% | SCHEDULE 13G ↗ |
| May 21, 2026 | SCHEDULE 13G | SANA Sana Biotechnology, Inc. | Peter Kolchinsky | 18.75M | 6.3% | SCHEDULE 13G ↗ |
| May 21, 2026 | SCHEDULE 13G | SANA Sana Biotechnology, Inc. | RA Capital Management, L.P. | 18.75M | 6.3% | SCHEDULE 13G ↗ |
| Jan 21, 2026 | SCHEDULE 13G | SANA Sana Biotechnology, Inc. | BlackRock, Inc. | 13.64M | 5.1% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | Kristina Burow | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | Steven Gillis | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | Robert Nelsen | 46.09M | 17.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | Clinton Bybee | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | Keith Crandell | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Partners X, LLC | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Partners IX, LLC | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Partners X, L.P. | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Partners X Overage, L.P. | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Partners IX Overage, L.P. | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Partners IX, L.P. | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Fund X Overage, L.P. | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Fund X, L.P. | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Fund IX Overage, L.P. | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | ARCH Venture Fund IX, L.P. | 45.86M | 17.2% | SCHEDULE 13G/A ↗ |
| Apr 25, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | BlackRock, Inc. | 11.03M | 4.9% | SCHEDULE 13G/A ↗ |
| Jan 31, 2025 | SCHEDULE 13G/A (amended) | SANA Sana Biotechnology, Inc. | The Vanguard Group | 10.75M | 4.8% | SCHEDULE 13G/A ↗ |
39 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 10:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances